Biomedical Research Institute from Catalonia (Spain) linked to a large reference hospital offers its expertise to join consortia

Participation in Horizon Europe and previous EU Framework Programmes.
Along Horizon Europe, 44 projects have been granted to our institution, 11 coordinated and 33 as partner, with a total economic return of €29.7M (89 funded projects with a return of €36.81M along H2020).
So far, IDIBAPS has participated in 4 Cancer Mission projects, coordinating 3 of them.

Cancer Research at IDIBAPS.

IDIBAPS hosts a strong and multidisciplinary Cancer Research Programme that covers the full translational pipeline, from molecular biology and preclinical models to clinical trials and patient care. The programme brings together over 25 research groups and is organized around five major areas: solid tumours, haematological malignancies, cancer immunotherapy, biomarkers and precision oncology, and tumour microenvironment and metastasis.
More information: https://www.clinicbarcelona.org/en/idibaps/areas-and-programs/cancer

We work across multiple cancer types, including breast cancer, colorectal cancer, prostate cancer, lung cancer, and haematological malignancies. We are also active in cancer diagnostics, biomarker discovery, and the development of targeted therapies and immunotherapy approaches.

Our main roles in European projects

• Clinical and basic research

• Providing clinical expertise, cohorts and data

• Clinical studies for development and validation of new technologies

Patient care context

University Hospital founded in 1906
4,500 professionals covering almost all medical and surgical specialties
High-complexity tertiary hospital part of the Catalan Public Hospital Network, serving as a Community Hospital (Barcelona), a reference hospital in Catalonia, Spain, and worldwide
Ranked #2 best renowned public hospital in Spain (Merco) and #63 worldwide (Newsweek)

Our added value

• High number of clinical trials: experience in development, implementation, regulatory and ethics approval

• Internationally recognized KOLs in different fields

• Strong translational research with focus on industrial and clinical implementation